Table 1.
Hypermethylation of the G0S2 locus independently predicts poor clinical outcomes.
| Recurrence | Death | ||||||
|---|---|---|---|---|---|---|---|
| Variable (Univariable model) | HR | 95% CI | p-value | Variable (Univariable model) | HR | 95% CI | p-value |
| Male v. Female (N = 47) | 0.560 | 0.216 to 1.45 | 0.233 | Male v. Female (N = 80) | 0.852 | 0.450 to 1.61 | 0.622 |
| Cortisol-secreting v. Non-cortisol-secreting (N = 47) | 2.58 | 0.996 to 6.66 | 0.0509 | Cortisol-secreting v. Non-cortisol-secreting (N = 80) | 2.86 | 1.36 to 5.99 | 5.45 × 10−3 |
| Stage at diagnosis (N = 47) | Stage at diagnosis (N = 80) | ||||||
| ENSAT III v. II & I | 1.49 | 0.602 to 3.70 | 0.388 | ENSAT III v. II & I | 2.09 | 0.937 to 4.66 | 0.0718 |
| ENSAT IV v. II & I | 5.26 | 2.52 to 11.0 | 1.03 × 10−5 | ||||
| Tumor size (cm) (N = 45) | 1.09 | 0.992 to 1.20 | 0.0739 | Tumor size (cm) (N = 75) | 1.16 | 1.08 to 1.24 | 7.71 × 10−5 |
| Tumor weight (g) (N = 36) | 1.0003 | 0.9995 to 1.0011 | 0.444 | Tumor weight (g) (N = 55) | 1.0007 | 1.0003 to 1.0011 | 4.59 × 10−4 |
| High grade v. Low grade (N = 42) | 3.15 | 1.21 to 8.16 | 0.0183 | High grade v. Low grade (N = 69) | 3.42 | 1.74 to 6.74 | 3.80 × 10−4 |
| G0S2 M v. UM (N = 47) | 6.91 | 2.74 to 17.5 | 4.31 × 10−5 | G0S2 M v. UM (N = 80) | 2.65 | 1.45 to 4.86 | 1.60 × 10−3 |
| Variable (Multivariable model) | HR | 95% CI | p-value | Variable (Multivariable model) | HR | 95% CI | p-value |
| (N = 47) | (N = 80) | ||||||
| Cortisol-secreting v. Non-cortisol-secreting | 2.51 | 0.964 to 6.53 | 0.0594 | Cortisol-secreting v. Non-cortisol-secreting | 2.43 | 1.14 to 5.16 | 0.0208 |
| G0S2 M v. UM | 6.88 | 2.71 to 17.5 | 5.02 × 10−5 | G0S2 M v. UM | 2.27 | 1.23 to 4.20 | 9.00 × 10−3 |
| (N = 47) | (N = 80) | ||||||
| ENSAT III v. II & I | 1.11 | 0.440 to 2.78 | 0.830 | ENSAT III v. II & I | 1.80 | 0.804 to 4.04 | 0.153 |
| ENSAT IV v. II & I | 5.44 | 2.57 to 11.5 | 9.30 × 10−6 | ||||
| G0S2 M v. UM | 6.81 | 2.67 to 17.4 | 5.98 × 10−5 | G0S2 M v. UM | 2.77 | 1.48 to 5.19 | 1.39 × 10−3 |
| (N = 45) | (N = 75) | ||||||
| Tumor size (cm) | 1.09 | 0.982 to 1.20 | 0.108 | Tumor size (cm) | 1.17 | 1.09 to 1.26 | 3.72 × 10−5 |
| G0S2 M v. UM | 6.95 | 2.71 to 17.8 | 5.33 × 10−5 | G0S2 M v. UM | 3.53 | 1.85 to 6.75 | 1.36 × 10−4 |
| (N = 36) | (N = 55) | ||||||
| Tumor weight (g) | 1.0005 | 0.9997 to 1.0012 | 0.208 | Tumor weight (g) | 1.0009 | 1.0005 to 1.0013 | 2.78 × 10−5 |
| G0S2 M v. UM | 7.10 | 2.55 to 19.8 | 1.78 × 10−4 | G0S2 M v. UM | 4.51 | 2.01 to 10.1 | 2.48 × 10−4 |
| (N = 42) | (N = 69) | ||||||
| High grade v. Low grade | 3.38 | 1.27 to 8.98 | 0.0147 | High grade v. Low grade | 3.10 | 1.56 to 6.17 | 1.25 × 10−3 |
| G0S2 M v. UM | 7.90 | 2.86 to 21.8 | 6.69 × 10−5 | G0S2 M v. UM | 3.05 | 1.54 to 6.05 | 1.43 × 10−3 |
NOTE. Hazard ratios (HR) and 95% confidence intervals (95% CI) were determined by Cox proportional hazards regression using available clinical and molecular data from all tumors in the FMUSP+UM Primary ACC Cohort. In each category, N indicates number of samples included in each univariable or multivariable model. The p-value is calculated from the Wald statistic using a chi-squared distribution. Grade is calculated on the basis of mitotic counts, where ≤ 20 mitoses/50 high-powered fields (HPF) is “Low grade” and > 20/50 HPF is “High grade.” “G0S2 M. v. UM” = G0S2 Methylated v. Unmethylated.